Contact Us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right. 

3047 North Sawyer Avenue
Chicago, IL, 60618
United States

(646) 267-2518

Medtrition Middle East provides high quality medical foods that are clinically supported to achieve the outcomes desired in a cost-effective way.  Whether it be Iraq, Saudi Arabia, Lebanon, or any other Middle Eastern country, the medical food’s that Medtrition Middle East can provide to address such things as renal and dialysis, protein and calorie malnutrition, pressure ulcers, wound healing, bowel management and more are second to none.  

Clinical Studies

 

clinical studies

 
 
11444 ProSource TF.jpg

espen 2016 Critical care: Meeting protein requirements without overfeeding Energy

Department of Nutrition & Dietetics, Southmead Hospital, Bristol, United Kingdom by Dr. Stephen Taylor.

Highlights Medtrition’s ProSource® TF was able to meet up to 94% of protein requirements in critical care patients than enteral formula alone. “Complimenting NPP feed to the nearest protein supplement pack, without overfeeding energy, increased the number of prescriptions meeting their respective guidelines by 10e90%; for local guidelines (FeedCalc) it increased from 32% to 73% using Pro-Source® TF or 82% using Prosource® Plus (both p < 0.001).” “Patients most at risk from protein ± glucose ± micronutrients deficits or energy overload are those with relatively low energy requirements due to small body size or being hypocalorically fed or receiving NNE, especially where Propofol displaces protein and carbohydrate. Complete feeds and protein supplements are complimentary. In practice a complete feed that supplies the protein and micronutrient requirements within energy expenditure would be most convenient. However, at present, enteral feeds (or PN solutions) don't adequately account for protein needs and NNE load. In these cases a protein supplement is necessary; protein ± glucose ± micronutrient supplementation may be needed when feed prescription is very limited.”

 
11220 ArgiMent AT Packet.jpg

THE CLINICAL AND ECONOMIC IMPACTS OF USING SUPPLEMENTAL ENTERAL NUTRITION FORMULAS IN HOSPITALIZED PATIENTS WHO ARE TAKING TOTAL PARENTERAL NUTRITION

INTERNATIONAL JOURNAL OF CURRENT MEDICAL AND PHARMACEUTICAL RESEARCH -King Hussein Medical Hospital, King Abdullah II St 230, Amman 11733, Jordanian Royal Medical Services by Dr. Mahmoud Bani Younes.

Highlights Medtrition’s ArgiMent® AT (Advanced Therapy) - “Across all analysis variables in our study, ArgiMent® had the highest significant positive clinical and economic outcomes due to the unique formulation characteristics of very high PD (≈26 g/100 Cal), High PRO quality (10 g of whey protein (WP)) ,high CD (≈2 Cal/ml), enrichment of immune enhancing nutrients (IENs) of GLT, arginine (ARG), and vitamin C, enrichment of prebiotic galcto-oligosaccharides (GOS or Bimuno), and enrichment of zinc which might also explain the significant highest liver ALB synthesis in short bowel syndrome (SBS) or other TPN indication scenarios in hospitalized patients with highly suspected zinc deficiency.”

 
11180 RenaMent Packet.jpg

The clinical and economic impacts of using high caloric and protein specialized versus standard nutritional enteral formulas in hypoalbumenic hospitalized patients

INTERNATIONAL JOURNAL OF CURRENT MEDICAL AND PHARMACEUTICAL RESEARCH -King Hussein Medical Hospital, King Abdullah II St 230, Amman 11733, Jordanian Royal Medical Services by Dr. Mahmoud Bani Younes.

Highlights Medtrition’s RenaMent® Raspberry Creme Flavor Powder Supplement - “The high protein biological value (BV) protein of RenaMent® may explain the significant higher difference of % change in albumin and % change in body weight when compared with other standard enteral nutrition formulas (ENFs). Ultimately, if we conserve albumin and lean body mass (LMB) from catabolism as possible, the consequences of morbidities and mortalities are expected to be lower and this correlation may explain the lower overall 28-day hospital mortality and overall hospital length of stay (LOS) in Group II (who took RenaMent®) compared with Group I (who was not taking RenaMent®).”